1. Improving Management of Secondary Hyperparathyroidism (SHPT) in Non-Dialysis Patients

2. CKD Is a Global Burden With Major Implications

3. CKD-MBD

4. Pathophysiology of CKD-MBD

5. Biochemical Phenotype of Disordered Mineral Metabolism in CKD

6. SHPT Is a Component of CKD-MBD Pathophysiology

7. Bone-Kidney-Parathyroid Endocrinological Feedback Loop

8. Vitamin D Metabolism: 1,25(OH)2 D Levels Are Tightly Regulated

9. Low Levels Of 25(OH)D (Calcifediol) Increase the Risk of Disease Progression and Mortality in Patients With CKD

10. Relationship Between 25(OH)D and PTH in CKD

11. Vitamin D Nomenclature

12. Relationship Between 25(OH)D and PTH Before and After Treatment With Vitamin D and Calcium for 8 Weeks

13. 2017 Revised KDIGO Guidelines PTH -- Vitamin D

14. 2017 Revised KDIGO Guidelines PTH -- Vitamin D (cont)

15. Management of Bone Mineral Parameters Remains the Therapeutic Goal

16. Management of PTH and Vitamin D

17. Ergocalciferol Treatment in Stage 3 and 4 CKD

18. Improved PTH With Calcitriol in CKD Stages 3 and 4

19. Oral Paricalcitol in Treatment of SHPT in CKD 3 & 4

20. Paricalcitol vs Calcitriol in CKD-MBD

21. Vitamin D Receptor Activators Did Not Improve CV Outcomes but Increased Hypercalcemia Risk

22. Ergocalciferol vs Paricalcitol for SHPT in CKD Stages 3 and 4

23. Calcifediol ER Increases 25(OH)D Levels And Reduces iPTH in Patients With Non-Dialysis CKD

24. Calcifediol ER Increased Serum Total 25-Hydroxyvitamin D: 1-Year Results

25. Calcifediol ER Lowers Plasma PTH Consistently Over Time

26. Calcifediol ER Has an Inconsequential Impact on Serum Calcium and Phosphorus

27. Comparison of Vitamin D Therapies for Stage 3-4 CKD

28. Summary and Conclusions

29. Abbreviations

30. Abbreviations (cont)